Latest Conference Articles

Community pharmacies have become one of the most accessible points of care for patients, especially in rural and underserved communities.

Pharmacists expand into vaccines and telehealth, but state laws and reimbursement gaps persist.

Medicare’s new GLP‑1 bridge program launches soon, easing access without shortages, and pharamcists are at the focal point of these transitions.

CMS pilots BALANCE and GLP-1 Bridge models to widen Medicare/Medicaid obesity drug coverage, spotlighting pharmacists’ role in access and safe therapy.

Drug pricing rules reshape pharmacy and manufacturer strategies, as transparency grows and 340B reforms intensify scrutiny.

Specialty pharmacy shifts toward holistic, empathetic care, easier oral therapies, and wider community access to advanced cell and gene treatments.

Pharmacy leaders face rapid change, which can boost agility and automate repetitive tasks.

These discussions focused on gaps in artificial intelligence, community-based advanced therapy, and demands of federal drug price negotiations.

Pharmacies can use technology and artificial intelligence to cut specialty drug complexity, boost access and adherence, and help pharmacists guide patients.

Pharmacy benefit manager reforms, gene therapy scale-up, artificial trust risks, and more reshape specialty pharmacy.

Real-time prescription pricing and auto-applied discounts cut pharmacy counter surprises, speed therapy, and free pharmacists for patient-focused care.

Lower patient caps shift costs to community pharmacies, fueling pharmacy benefit manager fees, mail-order growth, and pharmacy deserts.

Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, presents on the ever-expanding world of glucagon-like peptide-1s, now heading toward indications for chronic kidney disease and substance use disorder.

Benjamin Jolley, PharmD, presents on recent developments regarding pharmacy benefit manager reform on the state and federal levels.

Travis Wolff, PharmD, BCACP, presents on the current landscape of medical billing in pharmacy practice and the steps pharmacists can take to realize a significantly higher profit margin.

Suzanne K. Higginbotham, PharmD, BCACP, CTTS, CDCES, further discusses her APhA 2026 presentation titled “Real-Time. Real Change. Rethinking CGM for Today's Patient.”

This study indicates that stopping the medication is noninferior to continuing it indefinitely in terms of preventing death, recurrent heart attacks, or hospitalizations.

This benefit was primarily driven by significant reductions in nonfatal heart attacks and the need for revascularization procedures.

The study demonstrated that providing a combination of produce prescriptions, dietitian coaching, and artificial intelligence-optimized encouragement led to improved cardiovascular outcomes.

Ashley Chinchilla, PharmD, BCACP, presents on the persistence of vaccine hesitancy among patients and the powerful tools used to address it.

Darren Mensch, PharmD, BCPS, BCACP, joins to discuss his presentation at APhA 2026 titled “Quality Wars: The AI Awakens in Pharmacy Practice.”

Stefanie Ferreri, PharmD, BCACP, FCCP, FAPhA, presents on the increase of misinformation circulating among the public and how pharmacists can combat this phenomenon.

Sally Rafie, PharmD, BCPS, dives deeper into her APhA 2026 presentation titled “Lights, Camera, Access: Contraception Care at the Pharmacy.”

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, and Staci-Marie Norman, PharmD, CDCES, FAPhA, present on updates to the ADA Standards of Care in Diabetes.

A new study suggests that even though the profession is at a crossroads, the path toward improvement depends heavily on the setting in which a pharmacist practices.

Pharmacists lead safer postsurgical pain care, using multimodal nonopioid options and tight opioid stewardship from pre-operation through home.

Pharmacists help explain the complex evidence, address fears around injections and cost, and help patients integrate lifestyle changes alongside pharmacologic therapy for diabetes care.